Kintor Pharmaceutical's (HKG:9939) clinical observational study for its KX-826 drug combined with minoxidil for males with androgenetic alopecia in mainland China reached primary endpoints.
The drug company performed the study to improve the design of its phase 3 clinical trial, according to a Friday filing with the Hong Kong bourse.
The study involved two clinical research facilities in China and assessed hair growth and adverse events, among others, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。